ethyl 1-(2-(3-nitrophenyl)ethyl)-2,4,5-trioxoimidazolidine-3-acetate | 128043-80-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 1-(2-(3-nitrophenyl)ethyl)-2,4,5-trioxoimidazolidine-3-acetate
• 英文别名: Ethyl 2-[3-[2-(3-nitrophenyl)ethyl]-2,4,5-trioxoimidazolidin-1-yl]acetate
• CAS: 128043-80-1
• 化学式: C₁₅H₁₅N₃O₇
• 分子量: 349.3
• InChiKey: LNPQXYUZQHCXIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  130
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  ethyl 1-(2-(3-nitrophenyl)ethyl)-2,4,5-trioxoimidazolidine-3-acetate 在 盐酸 、 溶剂黄146 作用下， 反应 4.5h， 生成 3-Carboxymethyl-1-(2-(3-nitrophenyl)ethyl)parabanic acid
  参考文献：
  名称：

  Highly Selective Aldose Reductase Inhibitors. 1. 3-(Arylalkyl)-2,4,5-trioxoimidazolidine-1-acetic Acids

  摘要：

  A series of 3-(arylalkyl)-2,4,5-trioxoimidazolidine-1-acids (1) was prepared and tested for aldose reductase (AR) and aldehyde reductase (ALR) inhibitory activities. These compounds showed strong inhibitory activity against AR without significant inhibitory activity for ALR. The ratio of IC50(ALR)/IC50(AR) was > 1000 in some compouds. On the basis of pharmacological tests such as the recovery of reduced motor nerve conduction velocity and toxicological profile, 3-(3-nitrobenzyl)-2,4,5-trioxoimidazolidine-1-acid (NZ-314) was selected as the candidate for clinical development.

  DOI：

  10.1021/jm9508393
• 作为产物：
  描述：

  3-硝基苯乙胺 盐酸盐 在 盐酸 、 氢氧化钾 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 14.0h， 生成 ethyl 1-(2-(3-nitrophenyl)ethyl)-2,4,5-trioxoimidazolidine-3-acetate
  参考文献：
  名称：

  Highly Selective Aldose Reductase Inhibitors. 1. 3-(Arylalkyl)-2,4,5-trioxoimidazolidine-1-acetic Acids

  摘要：

  A series of 3-(arylalkyl)-2,4,5-trioxoimidazolidine-1-acids (1) was prepared and tested for aldose reductase (AR) and aldehyde reductase (ALR) inhibitory activities. These compounds showed strong inhibitory activity against AR without significant inhibitory activity for ALR. The ratio of IC50(ALR)/IC50(AR) was > 1000 in some compouds. On the basis of pharmacological tests such as the recovery of reduced motor nerve conduction velocity and toxicological profile, 3-(3-nitrobenzyl)-2,4,5-trioxoimidazolidine-1-acid (NZ-314) was selected as the candidate for clinical development.

  DOI：

  10.1021/jm9508393

文献信息

• Parabanic acid derivatives and pharmaceutical compositions containing them
  申请人：NIPPON ZOKI PHARMACEUTICAL CO. LTD.

  公开号：EP0353198A1

  公开（公告）日：1990-01-31

  The present invention relates to parabanic acid derivatives and pharmaceutically acceptable salts and metal complexes thereof having aldose reductase inhibitory activity. The compounds have the formula The compounds are useful as drugs for the treatment or prevention of diabetic conditions.

  本发明涉及具有醛糖还原酶抑制活性的对位苯甲酸衍生物及其药学上可接受的盐和金属复合物。这些化合物的化学式为 这些化合物可用作治疗或预防糖尿病的药物。
• US4985453A
  申请人：——

  公开号：US4985453A

  公开（公告）日：1991-01-15